Huge Plaintiffs' Victory Seen In First Actos® Trial

             Huge Plaintiffs' Victory Seen In First Actos® Trial

PR Newswire

NEW YORK, April 29, 2013

NEW YORK, April 29, 2013 /PRNewswire/ --Commenting on a $6.5 million dollar
verdict reached this past Friday in a Los Angeles courtroom against Takeda
Pharmaceuticals for injuries arising from the plaintiffs' ingestion of
Takeda's blockbuster selling diabetes drug, Actos®, Napoli Bern Ripka
Shkolnik, LLP Senior Partner Hunter Shkolnik described the verdict as "a
disaster for Takeda". In the California trial, a jury found that in marketing
Actos®, which has been linked to bladder cancer, Takeda had "failed to
adequately warn" physicians about Actos' bladder cancer risk and that this
failure was "a substantial factor" in causing injuries that may lead to the
death of the plaintiff, a California man. Jurors awarded $5 million in
compensatory damages to the patient and $1.5 million to his wife.

Losing the first of more than 3,000 Actos® suits that are slated for trial "is
devastating to the company," said Shkolnik, a New York-based attorney for
former Actos users, on Friday. "Takeda will be facing back-to-back trials of
far stronger cases next year," Shkolnik said. Shkolnik and Marc Jay Bern, both
Senior Partners of nationally-known plaintiffs' injury firm Napoli Bern Ripka
Shkolnik, LLP, are lead trial attorneys in the first trials that are scheduled
to commence in Chicago within the next year. The firm's partners have been
part of a small team of lawyers spearheading the efforts against Takeda
Pharmaceuticals in Cook County where there are currently in excess of 2000
Actos® bladder cancer claims on file. The litigation has been moving
aggressively forward under the team's supervision.

Actos® (pioglitazone) is a treatment for type 2 diabetes. Available only by
prescription, pioglitazone is in a class of medications called
thiazolidinediones, which work in the body to balance blood sugar by
increasing cells' receptiveness to insulin. Patients may have taken this drug
under the brand name Actos® or under other brand names such as Actoplus Met®
(a combination of pioglitazone and metformin) or Duetact® (pioglitazone and
glimepiride).

More than two million Americans with type 2 diabetes take Actos® and many are
increasingly concerned about its potential side effects. Actos® is the most
prescribed medication for the treatment of type 2 diabetes, generating 3.4
billion in sales in 2009. Recent studies have shown a link between this
medication and bladder cancer.

Press Release Contact Information:
Marc Jay Bern
Senior Partner
Napoli Bern Ripka Shkolnik, LLP
516-361-4909
mjbern@napolibern.com

This release was issued through WebWire(R). For more information visit
http://www.webwire.com.

SOURCE Napoli Bern Ripka Shkolnik, LLP
 
Press spacebar to pause and continue. Press esc to stop.